Second SEC investigation of SAC Capital


The Securities and Exchange Commission (SEC) has launched a civil investigation to determine whether the hedge fund management firm SAC Capital Advisors LP (USD14bn in assets) made inappropriate use of information from an expert network to make a large-scale investment in shares in Cougar Biotechnology ahead of the announcement of the firmâ€™s acquisition by Johnson & Johnson on 21 May.So far, the SEC has not accused SAC Capital of wrongdoing.The Wall Street Journal reports that since June, SAC Capital has been under investigation for similar moves ahead of the acquisition of MedImmune for USD15bn in 2007.